Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation

Journal of Clinical Oncology

Volumn 13, Issue 4, 1995, Pages 894-901

  Villablanca, Judith G ^a   Khan, Anis A ^b   Avramis, Vassilios I ^b   Seeger, Robert C ^b   Matthay, Katherine K ^b   Ramsay, Norma K C ^b   Reynolds, C Patrick ^b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ISOTRETINOIN; RETINOIC ACID;

ANEMIA; ARTICLE; BONE MARROW METASTASIS; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; VOMITING;

EID: 0028901770     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.4.894     Document Type: Article

References (43)

1. Seeger RC, Reynolds CP: Treatment of high risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am 38:393-424, 1991
2. Sidell N, Altman A, Haussler MR, et al: Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res 148:21-30, 1983
3. Reynolds CP, Kane DJ, Einhorn PA, et al: Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 366:203-211, 1991
4. Thiele CJ, Reynolds CP, Israel MA: Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313:404-406, 1985
5. Reynolds CP, Schindler P, Jones D, Gentile J, Proffitt R, Einhorn P: Comparison of 13-cis-retinoic acid to trans-retinoic acid using human neuroblastoma cell lines, in Evans A, Biedler JL, Brodeur G, et al (eds): Advances in Neuroblastoma Research 4. New York, NY, Wiley, 1994, pp 237-244
6. Li C, Reynolds CP: Expression of retinoic acid receptors alpha, beta, and gamma in human neuroblastoma cell lines, in Evans AE, Biedler JL, Brodeur GM, et al (eds): Advances in Neuroblastoma Research 4. New York, NY, Wiley, 1994, pp 221-227
7. Lippman SM, Meyskens F Jr: Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 107:499-501, 1987
8. Kessler JF, Jones SE, Levine N, et al: Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 123:201-204, 1987
9. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al: 13-cis-retinoic acid plus interferon alpha-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241-245, 1992
10. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al: 13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst 85:499-500, 1993
11. Kraemer KH, DiGiovanna JJ, Moshell AN, et al: Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 318:1633-1637, 1988
12. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1990
13. Finklestein JZ, Krailo MD, Lenarsky C, et al: 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: Report from the Childrens Cancer Study Group. Med Pediatr Oncol 20:307-311, 1992
14. Olson JA: Adverse effects of large doses of vitamin A and retinoids. Semin Oncol 10:290-293, 1983
15. Brodeur GM, Seeger RC, Barrett A, et al: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6:1874-1881, 1988
16. Reynolds CP, Moss TJ, Seeger RC, et al: Sensitive detection of neuroblastoma cells in bone marrow for monitoring the efficacy of marrow purging procedures. Prog Clin Biol Res 175:425-441, 1985
17. Moss TJ, Seeger RC, Kindler-Rohrbom A, et al: Immunohistologic detection and phenotyping of neuroblastoma cells in bone marrow using cytoplasmic neuron specific enolase and cell surface antigens. Prog Clin Biol Res 175:367-378, 1985
18. Hultin TA, Mehta RG, Moon RC: Simple high-performance liquid chromatographic method for the separation of retinoids including N-(4-hydroxyphenyl)-all-trans-retinamide. J Chromatogr 341: 187-192, 1985
19. Seeger RC, Moss TJ, Feig SA, et al: Bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res 271:203-213, 1988
20. Matthay KK, Seeger RC, Reynolds CP, et al: Comparison of autologous and allogeneic bone marrow transplantation for neuroblastoma. Proc Am Soc Clin Oncol 12:414, 1993 (abstr 1419)
21. Khan AA, Villablanca JG, Reynolds CP, et al: Pharmacokinetics of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. Proc Am Soc Clin Oncol 11:135, 1992 (abstr 360)
22. Villablanca JG, Khan AA, Avramis VI, et al: Hypercalcemia: A dose limiting toxicity associated with 13-cis-retinoic acid. Am J Pediatr Hematol 15:410-415, 1993
23. Cassidy J, Lippman M, Lacroix A, et al: Phase 11 trial of 13-cis-retinoic acid in metastatic breast cancer. Eur J Cancer Clin Oncol 18:925-928, 1982
24. Smith MA, Adamson PC, Balis FM, et al: Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 10:1666-1673, 1992
25. Chen ZX, Xue YQ, Zhang R, et al: A clinical and experimental study on all trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78:1413-1419, 1991
26. Castaigne S, Chomienne C, Daniel MT, et al: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704-1709, 1990
27. Lee JS, Newman RA, Lippman SM, et al: Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. J Clin Oncol 11:959-966, 1993
28. Frame B, Jackson CE, Reynolds WA, et al: Hypercalcemia and skeletal effects in chronic hypervitaminosis A. Ann Int Med 80:44-48, 1974
29. Fisher G, Skillern PG: Hypercalcemia due to hypervitaminosis A. JAMA 227:1413-1414, 1974
30. Katz CM, Tzagournis M: Chronic adult hypervitaminosis A with hypercalcemia. Metabolism 21:1171-1176, 1972
31. Bush ME, Dahms BB: Fatal hypervitaminosis A in a neonate. Arch Pathol Lab Med 108:838-842, 1984
32. Jowsey J, Riggs BL: Bone changes in a patient with hypervitaminosis A. J Clin Endocrinol Metab 28:1833-1835, 1968
33. Barnicott NA, Datta SP: Vitamin A and bone, in Bourne GH (ed): Biochemistry and Physiology of Bone II. New York, NY, Academic, 1972, pp 197-229
34. Barnicott NA: Local action of vitamin A on bone. J Anat 84:374-387, 1950
35. Ruby LK, Mital MA: Skeletal deformities following chronic hypervitaminosis A. J Bone Joint Surg 56A:1283-1287, 1974
36. DiGiovanna JJ, Peck GL: Oral synthetic retinoid treatment in children. Pediatr Dermatol 1:77-88, 1983
37. Smith MA, Parkinson DR, Cheson BD, et al: Retinoids in cancer therapy. J Clin Oncol 10:839-864, 1992
38. Muindi J, Frankel SR, Miller W, Jr., et al: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 79:299-303, 1992
39. Kalin JR, Wells MJ, Hill DL: Effects of phenobarbital, 3-methylcholanthrene, and retinoid pretreatment on disposition of orally administered retinoids in mice. Drug Metab Dispos 12:63-67, 1984
40. Siegenthaler G, Saurat JH: Plasma and skin carriers for natural and synthetic retinoids. Arch Dermatol 123:1690a-1692a, 1987
41. Hirschel Scholz S, Siegenthaler G, Saurat JH: Ligand-specific and non-specific in vivo modulation of human epidermal cellular retinoic acid binding protein (CRABP). Eur J Clin Invest 19:220-227, 1989
42. Hirschel Scholz S, Siegenthaler G, Saurat JH: Isotretinoin differs from other synthetic retinoids in its modulation of human cellular retinoic acid binding protein (CRABP). Br J Dermatol 120:639-644, 1989
43. Chomienne C, Ballerini P, Balitrand N, et al: Retinoic acid therapy for promyelocytic leukaemia. Lancet 2:746-747, 1989 (letter)